Golden Biotechnology
Taipei, Taiwan· Est.
Taiwan biotech advancing Antroquinonol for pancreatic cancer with Phase III trials underway.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwan biotech advancing Antroquinonol for pancreatic cancer with Phase III trials underway.
OncologyInfectious Disease
Technology Platform
Antroquinonol (Hocena), a natural compound from Antrodia camphorata, formulated for enhanced bioavailability and anti‑tumor activity via NF‑κB inhibition and apoptosis induction.
Opportunities
Successful Phase III results could enable rapid market entry in pancreatic cancer and provide a platform for expanding Antroquinonol into other oncology and inflammatory indications.
Risk Factors
Clinical failure in Phase III, regulatory hurdles, and reliance on external financing could delay or prevent commercialization.
Competitive Landscape
GBC competes with established pancreatic cancer therapies (e.g., nab‑paclitaxel + gemcitabine, FOLFIRINOX) and other late‑stage biotech firms; its natural‑product differentiation may offer a unique safety and efficacy profile.